RxDoctor Payments DataLook up a doctor →

Sergio Rovner, MD

Endocrinology, Diabetes & Metabolism · El Paso, TXNPI 1437164803

Payments from drug & device makers

$2,856,476in general payments, 2019–2025

Across 3,226 payments — averaging $885.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$707K
  • Eli Lilly$311K
  • AstraZeneca$264K
  • Sanofi US Services Inc.$233K
  • Boehringer Ingelheim International GmbH$229K
  • Lilly USA, LLC$217K
  • plus $895K from 54 others
$3,888in research payments, 2019–2025

Across 15 payments — averaging $259.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K
  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)140$706,805
Eli Lilly12$310,940
AstraZeneca(2 entities)147$263,949
Sanofi US Services Inc.37$233,372
Boehringer Ingelheim International GmbH45$228,936
Lilly USA, LLC499$217,334
Boehringer Ingelheim Pharma GmbH & Co.kg13$195,183
Corcept Therapeutics152$140,010
Novo Nordisk311$98,809
Novo Nordisk AS366$79,194
Boehringer Ingelheim132$73,970
Amgen(2 entities)308$73,533
Bayer138$45,096
Alnylam Pharmaceuticals Inc.8$34,482
Sanofi-aventis U.S. LLC83$33,730
Lexicon Pharmaceuticals, Inc.1$25,668
Amarin Pharma, Inc.55$21,056
GSK3$15,440
Dexcom, Inc.97$11,702
Johnson & Johnson34$8,504
Kowa Research Institute, Inc.4$5,917
Takeda Pharmaceuticals U.S.A., Inc.12$5,475
Esperion Therapeutics, Inc.26$4,783
Abbott93$4,714
Shire North American Group Inc4$4,335
Merck26$2,280
Medtronic(2 entities)53$1,938
Recordati_rare_diseases_inc.35$1,257
Insulet Corporation72$1,250
Radius Health, Inc.48$855
Novartis32$693
Xeris Pharmaceuticals, Inc.30$643
Tandem Diabetes Care, Inc.25$536
Antares Pharma, Inc.30$429
Regeneron Healthcare Solutions, Inc.13$346
Inspire Medical Systems, Inc.5$315
BETA Bionics, Inc.11$279
Pfizer12$267
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$252
Neurocrine Biosciences, Inc.4$249
Biohaven Pharmaceuticals, Inc.12$248
Mannkind Corporation10$243
EUSA Pharma (US) LLC4$239
Madrigal Pharmaceuticals10$208
Ultragenyx Pharmaceutical Inc.5$96
Ascendis Pharma Endocrinology Inc4$93
Kowa Pharmaceuticals America, Inc.6$89
Biohaven Pharmaceutical Holding Company Ltd.6$89
Kyowa Kirin, Inc.3$72
Eisai Inc.5$67
Astellas Pharma US Inc3$61
Vifor Pharma, Inc.3$60
Amryt Pharma Holdings Ltd3$54
Ionis Pharmaceuticals, Inc.2$46
Ascensia Diabetes Care US Inc.2$43
Chiesi USA, Inc.2$40
Halozyme Inc2$29
IBSA Pharma Inc.2$29
Avion Pharmaceuticals2$27
Ipsen Biopharmaceuticals, Inc1$27

How this compares

$2,856,476 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$124,051
Medicare patients
422
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in El Paso

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →